Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Kastrati, J. Mehilli, F. Neumann, F. Dotzer, J. Berg, H. Bollwein, Isolde Graf, Maryam Ibrahim, J. Pache, M. Seyfarth, H. Schühlen, J. Dirschinger, P. Berger, A. Schömig (2006)
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.JAMA, 295 13
G. Stone, B. McLaurin, David Cox, Michel Bertrand, A. Lincoff, Jeffrey Moses, Harvey White, S. Pocock, James Ware, F. Feit, P. Aylward, Angel Cequier, W. Desmet, R. Ebrahimi, M. Hamon, L. Rasmussen, H. Rupprecht, J. Hoekstra, R. Mehran, E. Ohman (2006)
Bivalirudin for patients with acute coronary syndromes.The New England journal of medicine, 355 21
S. Savonitto, D. Ardissino, C. Granger, G. Morando, M. Prando, A. Mafrici, C. Cavallini, G. Melandri, T. Thompson, A. Vahanian, E. Ohman, R. Califf, F. Werf, E. Topol (1999)
Prognostic value of the admission electrocardiogram in acute coronary syndromes.JAMA, 281 8
D. Angiolillo, A. Fernández-Ortiz, E. Bernardo, C. Ramírez, M. Sabaté, C. Bañuelos, R. Hernández-Antolı́n, J. Escaned, R. Moreno, F. Alfonso, C. Macaya (2004)
High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.European heart journal, 25 21
Mehta Mehta, Yusuf Yusuf, Peters Peters (2001)
Effects of pretreatment with clopidogrel and aspirin followed by long‐term therapy in patients undergoing percutaneous coronary intervention: The PCI‐CURE studyLancet, 358
A. Kastrati, J. Mehilli, H. Schühlen, J. Dirschinger, F. Dotzer, J. Berg, F. Neumann, H. Bollwein, Christian Volmer, M. Gawaz, P. Berger, A. Schömig (2004)
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.The New England journal of medicine, 350 3
J. Delaney, L. Opatrny, J. Brophy, S. Suissa (2007)
Drug–drug interactions between antithrombotic medications and the risk of gastrointestinal bleedingCanadian Medical Association Journal, 177
J. Reynolds, G. Ahearn, M. Angelo, Jian Zhang, F. Cobb, J. Stamler (2007)
S-nitrosohemoglobin deficiency: A mechanism for loss of physiological activity in banked bloodProceedings of the National Academy of Sciences, 104
G. Stone, M. Bertrand, J. Moses, E. Ohman, A. Lincoff, J. Ware, S. Pocock, B. McLaurin, D. Cox, M. Jafar, H. Chandna, F. Hartmann, F. Leisch, R. Strasser, M. Desaga, T. Stuckey, R. Zelman, I. Lieber, D. Cohen, R. Mehran, H. White, for Investigators (2007)
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.JAMA, 297 6
Anderson (2007)
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic SurgeonsJ Am Coll Cardiol, 50
E. Antman, M. Cohen, P. Bernink, C. Mccabe, T. Horácek, G. Papuchis, B. Mautner, R. Corbalán, D. Radley, E. Braunwald (2000)
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.JAMA, 284 7
D. Sibbing, Gabriele Busch, S. Braun, Stefan Jawansky, A. Schömig, A. Kastrati, I. Ott, N. Beckerath (2008)
Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention.European heart journal, 29 12
J. Marmur, C. Mitre, E. Barnathan, E. Cavuşoğlu (2006)
Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.American heart journal, 152 5
D. Sica (2002)
The implications of renal impairment among patients undergoing percutaneous coronary intervention.The Journal of invasive cardiology, 14 Suppl B
Gruberg Gruberg
Clopidogrel preload prior to percutaneous coronary intervention: The ARMYDA‐4 and ARMYDA‐5 trialsMedscape Cardiol.
W. Rosamond, K. Flegal, K. Furie, A. Go, K. Greenlund, Nancy Haase, S. Hailpern, Michael Ho, V. Howard, B. Kissela, S. Kittner, D. Lloyd‐Jones, M. McDermott, J. Meigs, C. Moy, G. Nichol, Christopher O'Donnell, V. Roger, P. Sorlie, J. Steinberger, T. Thom, M. Wilson, Yuling Hong (2007)
Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation, 117 4
P. Sonveaux, I. Lobysheva, O. Féron, T. McMahon (2007)
Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery.Physiology, 22
Moliterno
Advances in antiplatelet/antithrombotic therapy for ACS and PCIJ Interven Cardiol (in press).
Ajay Kirtane, G. Piazza, S. Murphy, D. Budiu, David Morrow, David Cohen, E. Peterson, N. Lakkis, Howard Herrmann, T. Palabrica, C. Gibson (2006)
Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial.Journal of the American College of Cardiology, 47 12
R. Mehta, J. Alexander, F. Werf, P. Armstrong, K. Pieper, Jyotsna Garg, R. Califf, C. Granger (2005)
Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes.JAMA, 293 14
J. Pache, A. Kastrati, J. Mehilli, M. Gawaz, F. Neumann, M. Seyfarth, D. Hall, S. Braun, J. Dirschinger, A. Schömig (2002)
Clopidogrel therapy in patients undergoing coronary stenting: Value of a high‐loading‐dose regimenCatheterization and Cardiovascular Interventions, 55
Caroline Milton, Prashanthan Sanders, P. Steele (2001)
For personal use. Only reproduce with permission from The Lancet Publishing Group. Late cardiopulmonary complication of ventriculo-atrial shunt
R. Mehta, M. Roe, Jyotsna Mulgund, E. Ohman, C. Cannon, W. Gibler, C. Pollack, Sidney Smith, T. Ferguson, E. Peterson (2006)
Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery.Journal of the American College of Cardiology, 48 2
M. Sabatine, Hussam Hamdalla, S. Mehta, K. Fox, E. Topol, S. Steinhubl, C. Cannon (2008)
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.American heart journal, 155 5
C. Gibson, D. Morrow, S. Murphy, T. Palabrica, L. Jennings, P. Stone, Henry Lui, T. Bulle, N. Lakkis, R. Kovach, D. Cohen, P. Fish, C. Mccabe, E. Braunwald (2006)
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.Journal of the American College of Cardiology, 47 12
K. Alexander, A. Chen, M. Roe, L. Newby, C. Gibson, Nancy Allen-LaPointe, C. Pollack, W. Gibler, E. Ohman, E. Peterson (2005)
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.JAMA, 294 24
Balance between efficacy and safety is a major concern in therapeutic interventions of patients with acute coronary syndromes. Identifying and managing the risks that may negatively affect this balance can potentially minimize the incidence of morbidity and/or mortality among patients with acute coronary syndromes. Unstable angina and non‐ST‐elevation myocardial infarction are potentially life‐threatening disorders and a major cause of hospitalization and emergency medical care. At the time of presentation, the use of algorithms that provide reasonable assessment of a patient's risk of cardiovascular events, such as the Thrombolysis in Myocardial Infarction risk score, can help clinicians identify which patients will most likely benefit from a specific strategy. The ultimate goal of treatment for non‐ST‐elevation myocardial infarction is to reduce short‐ and long‐term morbidity and mortality, as well as salvage myocardial cells and cardiac function. Pharmacologic intervention with antiplatelet and/or antithrombotic agents has proven to be effective in achieving this goal in numerous outcome studies. However, clinicians must balance anti‐ischemic efficacy with the need to minimize the risk of serious bleeding complications (e.g., hemorrhage). Issues related to safety include timing of the dose, duration of infusion, drug compatibility, errors in estimating a patient's weight and/or age, failure to adjust the dosage based upon renal function, and errors in drug preparation.
Journal of Interventional Cardiology – Wiley
Published: Dec 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.